Literature DB >> 31123033

Preclinical evidence for an effective therapeutic activity of FL118, a novel survivin inhibitor, in patients with relapsed/refractory multiple myeloma.

Lisa C Holthof1, Hilma J van der Horst1, Susan E van Hal-van Veen1, Ruud W J Ruiter1, Fengzhi Li2, Marijke Buijze3, Morten N Andersen4,5,6, Huipin Yuan7, Joost de Bruijn7,8, Niels W C J van de Donk1, Henk M Lokhorst1, Sonja Zweegman1, Richard W J Groen9, Tuna Mutis9.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31123033      PMCID： PMC7012462          DOI： 10.3324/haematol.2018.213314

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

Review 1.  Discovery of survivin inhibitors and beyond: FL118 as a proof of concept.

Authors:  Fengzhi Li
Journal:  Int Rev Cell Mol Biol       Date:  2013       Impact factor: 6.813

2.  Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma.

Authors:  Vikas A Gupta; Shannon M Matulis; Jason E Conage-Pough; Ajay K Nooka; Jonathan L Kaufman; Sagar Lonial; Lawrence H Boise
Journal:  Blood       Date:  2017-02-01       Impact factor: 22.113

3.  FL118, a novel camptothecin analogue, overcomes irinotecan and topotecan resistance in human tumor xenograft models.

Authors:  Xiang Ling; Xiaojun Liu; Kai Zhong; Nicholas Smith; Joshua Prey; Fengzhi Li
Journal:  Am J Transl Res       Date:  2015-10-15       Impact factor: 4.060

4.  IAP family protein expression correlates with poor outcome of multiple myeloma patients in association with chemotherapy-induced overexpression of multidrug resistance genes.

Authors:  Yasunori Nakagawa; Shinya Abe; Morito Kurata; Maki Hasegawa; Kouhei Yamamoto; Miori Inoue; Tamiko Takemura; Kenshi Suzuki; Masanobu Kitagawa
Journal:  Am J Hematol       Date:  2006-11       Impact factor: 10.047

5.  Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab.

Authors:  Michael S van der Veer; Michel de Weers; Berris van Kessel; Joost M Bakker; Shulamiet Wittebol; Paul W H I Parren; Henk M Lokhorst; Tuna Mutis
Journal:  Haematologica       Date:  2010-11-25       Impact factor: 9.941

6.  Reconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myeloma.

Authors:  Richard W J Groen; Willy A Noort; Reinier A Raymakers; Henk-Jan Prins; Linda Aalders; Frans M Hofhuis; Petra Moerer; Jeroen F van Velzen; Andries C Bloem; Berris van Kessel; Henk Rozemuller; Ellen van Binsbergen; Arjan Buijs; Huipin Yuan; Joost D de Bruijn; Michel de Weers; Paul W H I Parren; Jan Jacob Schuringa; Henk M Lokhorst; Tuna Mutis; Anton C M Martens
Journal:  Blood       Date:  2012-05-31       Impact factor: 22.113

7.  Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells.

Authors:  Stephanie Markovina; Natalie S Callander; Shelby L O'Connor; Jihoon Kim; Jae E Werndli; Martha Raschko; Catherine P Leith; Brad S Kahl; Kyungmann Kim; Shigeki Miyamoto
Journal:  Mol Cancer Res       Date:  2008-08       Impact factor: 5.852

8.  Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity.

Authors:  Douglas W McMillin; Jake Delmore; Ellen Weisberg; Joseph M Negri; D Corey Geer; Steffen Klippel; Nicholas Mitsiades; Robert L Schlossman; Nikhil C Munshi; Andrew L Kung; James D Griffin; Paul G Richardson; Kenneth C Anderson; Constantine S Mitsiades
Journal:  Nat Med       Date:  2010-03-14       Impact factor: 53.440

9.  Accessory cells of the microenvironment protect multiple myeloma from T-cell cytotoxicity through cell adhesion-mediated immune resistance.

Authors:  Sanne J de Haart; Niels W C J van de Donk; Monique C Minnema; Julie H Huang; Tineke Aarts-Riemens; Niels Bovenschen; Huipin Yuan; Richard W J Groen; Douglas W McMillin; Jana Jakubikova; Henk M Lokhorst; Anton C Martens; Constantine S Mitsiades; Tuna Mutis
Journal:  Clin Cancer Res       Date:  2013-09-04       Impact factor: 13.801

Review 10.  Microenvironment drug resistance in multiple myeloma: emerging new players.

Authors:  Lucia Di Marzo; Vanessa Desantis; Antonio Giovanni Solimando; Simona Ruggieri; Tiziana Annese; Beatrice Nico; Ruggiero Fumarulo; Angelo Vacca; Maria Antonia Frassanito
Journal:  Oncotarget       Date:  2016-09-13
View more
  4 in total

Review 1.  Molecular Glues: Capable Protein-Binding Small Molecules That Can Change Protein-Protein Interactions and Interactomes for the Potential Treatment of Human Cancer and Neurodegenerative Diseases.

Authors:  Fengzhi Li; Ieman A M Aljahdali; Xiang Ling
Journal:  Int J Mol Sci       Date:  2022-06-01       Impact factor: 6.208

Review 2.  Cancer therapeutics using survivin BIRC5 as a target: what can we do after over two decades of study?

Authors:  Fengzhi Li; Ieman Aljahdali; Xiang Ling
Journal:  J Exp Clin Cancer Res       Date:  2019-08-22

Review 3.  Challenges for Immunotherapy in Multiple Myeloma: Bone Marrow Microenvironment-Mediated Immune Suppression and Immune Resistance.

Authors:  Lisa C Holthof; Tuna Mutis
Journal:  Cancers (Basel)       Date:  2020-04-17       Impact factor: 6.639

Review 4.  Emerging Importance of Survivin in Stem Cells and Cancer: the Development of New Cancer Therapeutics.

Authors:  Neerada Meenakshi Warrier; Prasoon Agarwal; Praveen Kumar
Journal:  Stem Cell Rev Rep       Date:  2020-10       Impact factor: 5.739
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.